Luteinizing Hormone and Prolactin Response to Buprenorphine in Depression and Schizophrenia

  • C. Schmauss
  • K. M. Pirke
  • D. E. Bremer
  • M. M. Weber
  • H. M. Emrich


An association of hyper- or hypoactivity of endogenous opioids with depressive and schizophrenic psychoses has, to date, not been convincingly demonstrated. Such an assumption could, however, imply an altered sensitivity of structures involved in the mediation of opioid effects. The effects of opioids on pituitary prolactin (PRL)1,2 and luteinizing hormone (LH) release3,4 in man are well described, and there is little doubt that these effects are mediated through distinct opioid receptor populations. We have demonstrated that the partial opioid agonist buprenorphine exerts both antidepressive and antischizophrenic effects.5 We report here on LH and PRL responses of depressed and schizophrenic patients to acute buprenorphine medication in comparison to respective responses of healthy volunteers.


Luteinizing Hormone Schizophrenic Patient Endogenous Opioid Prolactin Response Luteinizing Hormone Release 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Tolis G, Hikey J, Guyda H. Effect of morphine on serum growth hormone, cortisol, prolactin and thyroid stimulating hormone in man. J Clin Endocrinol Metab 1975; 41: 797–800.PubMedCrossRefGoogle Scholar
  2. 2.
    Mendelson JH, Ellinboe J, Mello NK, et al. Buprenorphine effects on plasma luteinizing hormone and prolactin in male heroin addicts. J Pharmacol Exp Ther 1982; 220: 252–255.PubMedGoogle Scholar
  3. 3.
    Delitala G, Devilla L, Arata L. Opiate receptors and anterior pituitary hormone secretion in man: effect of naloxone infusion. Acta Endocrinol (Copenh) 1981; 97: 150–156.Google Scholar
  4. 4.
    Veldhuis JD, Worgul TJ, Monsaert R, et al. A possible role for endogenous opioids in the control of prolactin and luteinizing hormone secretion in the human. J Endocrinol Invest 1981; 4: 31–35.PubMedGoogle Scholar
  5. 5.
    Schmauss C, Emrich HM. Narcotic antagonist and opioid treatment in psychiatry. In Rodgers RJ, Cooper SJ (eds): Endorphins, Opiates and behavioral Processes. London: Wiley 1987; 327–351.Google Scholar
  6. 6.
    Dum JE, Herz A. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br J Pharmacol 1981; 74: 627–633.PubMedGoogle Scholar
  7. 7.
    Extein J, Pottash ALC, Gold MS, et al. Deficient prolactin response to morphine in depressed patients. Am J Psychiatry 1980; 137: 845–846.PubMedGoogle Scholar
  8. 8.
    Judd LL, Risch S, Parker DC, et al. The effect of methadone challenge on the prolactin and growth hormone responses of psychiatric patients and normal controls. Psychopharmacol Bull 1983; 18: 204–207.Google Scholar
  9. 9.
    Robertson AG, Jackman H, Meltzer HY. Prolactin response to morphine in depression. Psychiatry Res 1984; 11: 353–364.PubMedCrossRefGoogle Scholar
  10. 10.
    Zis AP, Haskett RF, Albala AA, et al. Prolactin response to morphine in depression. Biol Psychiatry 1985; 20: 287–292.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1989

Authors and Affiliations

  • C. Schmauss
  • K. M. Pirke
  • D. E. Bremer
  • M. M. Weber
  • H. M. Emrich

There are no affiliations available

Personalised recommendations